Speakers 2022

Oliver Rinner


Founder & CEO of Biognosys AG, Switzerland


Oliver was a co-founder of Biognosys in 2008 and is leading the company as CEO, starting as a spin-off from ETH Zurich to a market-leading inventor and provider of proteomics technology that Biognosys is today. He holds a diploma in Psychology and Biochemistry from the University of Zurich and did his Ph.D. in psychophysics and behavioral molecular genetics at the ETH Zurich. In his post-doctoral studies in the group of Ruedi Aebersold (ETH), he developed algorithms and methods for quantitative mass spectrometry, which formed the basis for the technology that Biognosys develops today.

Bishoy Hanna

Medical Affairs is a function that plays a key role in drug development by generating impactful insights to help shape the company’s medical strategy. In his current position as a consultant working closely with the Global Medical Affairs team at Merck Healthcare KGaA, Bishoy has the chance to contribute to drug development and make an impact on the patients’ journey. Bishoy Hanna is originally from Egypt. He completed his Master’s in 2017 at the MSc/PhD Molecular Biology, Georg-August-Universität Göttingen, Germany. He was later awarded a Marie-Curie fellowship to pursue his PhD studies in the group of Professor Thomas Helleday at Karolinska Institute, Sweden. During his PhD studies, Bishoy focused on studying the oxidative DNA damage response in cancer and inflammatory conditions and how to exploit it using novel small-molecule inhibitors. Bishoy’s strong scientific background together with his passion for medical affairs enable him to support the development of Merck’s oncology portfolio in the field of DNA damage response (DDR) and ultimately help bring it to the clinic.

Chiara Pastore

Chiara has a first degree and a PhD in chemistry, obtained from the University of Pisa and from Scuola Normale Superiore, Pisa. During her PhD she focused on the structural biology and biochemistry of iron binding proteins, carrying out research in Pisa, at EMBL in Heidelberg and at the National Institute for Medical Research in London. She then moved to Columbia University in NYC to work on protein-RNA interactions at then back to the UK, at Imperial College London, where she studied viral proteins. She started her editorial career in October 2015 at Nature Communications and joined Nature Nanotechnology in June 2017, where she handles papers in the areas of nanobiotechnology and nanomedicine. Chiara is based in London.

Marc Gerauer

Dr. Gerauer studied chemistry at the Heinrich Heine University Düsseldorf and has experience in the field of organic and bioorganic chemistry. He received his doctorate at the University of Dortmund and the Max-Planck-Institute of Molecular Physiology. He has published in several high impact papers, like Celland Nature Chemical Biology. Between 2008 and 2010, Dr. Gerauer was trained in the field of intellectual property at a patent law firm in Düsseldorf. Dr. Gerauer qualified as German Patent Attorney in 2011 and subsequently joined Isenbruck Bösl Hörschler LLP. Dr. Gerauer qualified as European Patent Attorney in 2013 and joined Kraus & Weisert in 2017. For several years now, his primary practice has been focused on patents in the technical fields of organic chemistry, polymers, biochemistry, pharmaceutical chemistry, and related areas. His clients include small and medium-sized biotech businesses and companies in the pharmaceutical industry as well as academia. Dr. Gerauer provides qualified advice in the area of patent and trademark law with particular focus on questions regarding national and international prosecution and the defence and enforcement of protective rights against third parties.